Comparative Pharmacology
Head-to-head clinical analysis: LORTAB versus TYLOX 325.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORTAB versus TYLOX 325.
LORTAB vs TYLOX-325
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates pain pathways centrally.
Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.
1-2 tablets (each containing 5 mg hydrocodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain. Maximum acetaminophen 3000 mg/day.
1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.
None Documented
None Documented
Hydrocodone: 3.3-4.4 hours in adults; prolonged in hepatic/renal impairment (up to 6-8 hours). Clinical context: requires 4-6 hour dosing intervals; steady-state in ~24 hours.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Oxycodone: 3-5 hours (extended-release preparation); terminal half-life 4.5-5.5 hours. Clinical context: repeated dosing may lead to accumulation; half-life prolongation in elderly, renal or hepatic disease.
Renal: ~90% (unchanged: ~5% hydrocodone, ~60% hydromorphone and other conjugates; codeine-like metabolites). Biliary/fecal: minor (<10%).
Renal: acetaminophen metabolites (60-70% as glucuronide conjugate, 20-30% as sulfate conjugate, 5-10% as cysteine conjugate, 5% unchanged). Oxycodone: renal (primarily metabolites, <10% unchanged); biliary/fecal: minor (oxycodone metabolites).
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination